Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Fosun Acquires 60% Stake in Singapore Medical Center Chain for $158 Million

publication date: Jun 8, 2022

Shanghai Fosun Pharma will pay $158 million to acquire a 60% stake in a Singapore oncology medical center chain, Oncocare Medical Pte. Oncocare, with seven clinics in Singapore private medical centers, is one of Singapore’s largest private medical oncology specialist centers. Most of the purchase, a 51% Oncocare share, was acquired from Aurora Healthcare, a company controlled by Dianbo Liu, the chairman of Hong Kong-listed Lue Pharma. About 10% of Fosun’s revenues derive from hospitals/clinics, and the company plans to expand its medical services coverage in China and Southeast Asia. More details....

Stock Symbols: (HK: 2196; SHA: 600196)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital